TRANSCENTA HOLDING - A global Fully Integrated Biotherapeutics Company
Transcenta, biologics, antibody
Transcenta is a clinical stage biopharmaceutical company that fully integrates antibody-based biotherapeutics discovery, research, development and manufacturing. On September 29, 2021, Transcenta was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code: 06628.
Transcenta has established global footprint, with Headquarters and Discovery, Clinical and Translational Research Center in Suzhou, Process and Product Development Center and Manufacturing Facility in Hangzhou, and Clinical Development Centers in Beijing, Shanghai and Guangzhou in China and in Princeton, US, and External Partnering Center in Boston and Los Angeles, US. Transcenta is developing nine therapeutic antibody molecules for oncology and selected non-oncology indications including bone and kidney disorders.
CEO
EVP, Head of Global R&D and CMO
EVP, Chief Technology Officer
EVP, Chief Operating Officer
EVP, Global Process & Product Development
SVP, Finance & Business Operations
SVP, Research
SVP, DMPK & Translational Science
SVP, Global Clinical Development
SVP, Manufacturing
VP Commercial Planning and Business Development
Non-Executive Director and Chairman
Executive Director and CEO
Executive Director
Executive Director
Independent Non-executive Director
Independent Non-executive Director
Independent Non-executive Director
We have strong support from prominent shareholders, consisting of well-known global strategic investors and biotech-focused specialist funds, including Lilly Asia Ventures, Temasek, ARCH Ventures Partners, China Structural Reform Fund, Teng Yue Partners, Hillhouse Capital and Sequoia Capital China. Our shareholders have extensive experience managing and growing biopharmaceutical companies and share with us their knowledge and views to assist us from research and development to commercialization.
SVP Finance Business Operations
Albert has 15 years of experience in the financial field and has worked in the Audit and Trading Consulting department of PWC, providing IPO audits, annual audits, transaction due diligence, post management, transaction integration and other related financial advisory services. Over the past 10 years, he has been responsible for assisting clients to list in mainland China and Hong Kong's capital markets by verifying compliance with the rules of relevant capital market regulation and reporting. In addition, he also participated in a number of M&A consulting projects to assist domestic and foreign clients to carry out due diligence, design trading structure, to ensure smooth transactions, as well as to carry out the integration of the financial sector to improve the clients and the target companies’ financial system and processes. Albert has received his bachelor degree from Sun Yat-sen University and is a member of the CICPA and the ACCA.
